|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:age
|
adults 18 years and older
children 3 years and older (in some countries)
|
|
gptkbp:approvedBy
|
2020
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:countryOfOrigin
|
gptkb:China
|
|
gptkbp:dosingSchedule
|
two doses
|
|
gptkbp:efficacyAgainstSevereCOVID19
|
100% (Brazil trial)
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
51% (Brazil trial)
|
|
gptkbp:emergencyServices
|
gptkb:Argentina
gptkb:Azerbaijan
gptkb:Bolivia
gptkb:Brazil
gptkb:Cambodia
gptkb:Chile
gptkb:Colombia
gptkb:Dominican_Republic
gptkb:Ecuador
gptkb:Egypt
gptkb:Hong_Kong
gptkb:Indonesia
gptkb:Laos
gptkb:Malaysia
gptkb:Mexico
gptkb:Mongolia
gptkb:Morocco
gptkb:Nepal
gptkb:Pakistan
gptkb:Philippines
gptkb:Serbia
gptkb:Singapore
gptkb:Thailand
gptkb:Tunisia
gptkb:Turkey
gptkb:Ukraine
gptkb:Uruguay
gptkb:Venezuela
gptkb:World_Health_Organization
gptkb:Zimbabwe
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CoronaVac vaccine
|
|
gptkbp:manufacturer
|
gptkb:Sinovac_Biotech
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
pain at injection site
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
inactivated virus vaccine
|
|
gptkbp:WHOEmergencyUseListing
|
2021-06-01
|
|
gptkbp:bfsParent
|
gptkb:Yin_Weidong
|
|
gptkbp:bfsLayer
|
6
|